A photo of Bruce Trapnell.

Director, Transitional Pulmonary Science Center

Attending Physician, Pulmonologist - Research, Adult Clinical, Division of Pulmonary Medicine

Professor, UC Department of Pediatrics

513-636-6361

513-636-3723

Board Certified

My Biography & Research

Biography

Dr. Trapnell received his medical degree from the University of Maryland in 1985 and medical residency training at The Ohio State University Hospitals. He completed a fellowship in pulmonary medicine and then served as attending physician and senior attending physician at the Clinical Center of the National Institutes of Health. Subsequently, he served as vice president and director of the Division of Pulmonary and Virology Studies at Genetic Therapy, Incorporated, a subsidiary of Novartis.

In 1997, Dr. Trapnell joined Cincinnati Children’s Hospital Medical Center and is now a professor of Medicine and Pediatrics at the UC College of Medicine. At Cincinnati Children's, he directed Cincinnati’s Cystic Fibrosis Therapeutics Development Network Center for more than a decade and participated in numerous clinical trials as principal investigator including studies leading to FDA-approval of Creon® and Pancreaze®. He established and directs the Rare Lung Diseases Clinical Research Consortium (RLDC) in which a study led by Frank McCormack resulted in FDA approval of Sirolimus® as therapy of Lymphangioleiomyomatosis.

Dr. Trapnell’s research group established that GM-CSF autoantibodies caused the rare lung disease autoimmune pulmonary alveolar proteinosis and established clinical laboratory tests for its diagnosis and identified hereditary pulmonary alveolar proteinosis as a new genetic disease caused by mutations in CSF2RA and CSF2RB. His research group developed a novel type of cell transplantation, pulmonary macrophage transplantation, and is currently translating it for testing as therapy in patients with the disease. The group also contributed to the identification, characterization, and methods for diagnosis of indium-related lung disease.

An ardent patient advocate, Dr. Trapnell has worked with patient foundations for cystic fibrosis (CF), alpha-1-antitrypsin deficiency, pulmonary alveolar proteinosis, lymphangioleiomyomatosis, and childhood interstitial lung diseases. He has served as past scientific director for the Alpha-1 Foundation and as co-founder and current scientific director of the Pulmonary Alveolar Proteinosis Foundation. Since coming to Cincinnati, he has provided training in basic, clinical, and translational research at pre- and post-doctoral levels.

Clinical Interests

Research on rare lung diseases including pulmonary alveolar proteinosis; cystic fibrosis; alpha-1 antitrypsin deficiency; lymphangioleiomyomatosis

Research Interests

Alveolar macrophage function; molecular techniques using gene knockout, transgenic and conditional gene expression mouse models and non-human primates, in vitro and in vivo viral gene transfer, and bone marrow transplantation

Academic Affiliation

Professor, UC Department of Pediatrics

Departments

Pulmonary Medicine, Pulmonary Biology

Science Blog

My Education

BS: Biochemistry, University of Maryland, College Park, MD, 1978.

MS: Genetics, The George Washington University, Washington, DC, 1981.

MD: University of Maryland School of Medicine, Baltimore, MD, 1984.

Residency: Internal Medicine, The Ohio State University Hospitals, Columbus, OH, 1987.

Fellowship: Pulmonary Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, 1989.

Certification: Diplomat in Internal Medicine, American Board of Internal Medicine, 1987; Diplomat, National Board of Medical Examiners, 1987; Diplomat in Pulmonary Medicine, American Board of Internal Medicine, 2000.

My Publications

Long-Term Safety and Efficacy of Gene-Pulmonary Macrophage Transplantation Therapy of PAP in Csf2ra(-/-) Mice. Arumugam, P; Suzuki, T; Shima, K; McCarthy, C; Sallese, A; Wessendarp, M; Ma, Y; Meyer, J; Black, D; Chalk, C; et al. Molecular Therapy. 2019; 27:1597-1611.

Automated Parenchymal Pattern Analysis of Treatment Responses in Pulmonary Alveolar Proteinosis. McCarthy, C; Bartholmai, BJ; Woods, JC; McCormack, FX; Trapnell, BC. American Journal of Respiratory and Critical Care Medicine. 2019; 199:1151-1152.

Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis. Gupta, N; Lee, H; Young, LR; Strange, C; Moss, J; Singer, LG; Nakata, K; Barker, AF; Chapman, JT; Brantly, ML; et al. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2019; 53.

Pulmonary alveolar proteinosis: An autoimmune disease lacking an HLA association. Anderson, K; Carey, B; Martin, A; Roark, C; Chalk, C; Nowell-Bostic, M; Freed, B; Aubrey, M; Trapnell, B; Fontenot, A. PLoS ONE. 2019; 14.

Pulmonary alveolar proteinosis. Trapnell, BC; Nakata, K; Bonella, F; Campo, I; Griese, M; Hamilton, J; Wang, T; Morgan, C; Cottin, V; McCarthy, C. Nature Reviews Disease Primers. 2019; 5.

Blood Testing for Differential Diagnosis of Pulmonary Alveolar Proteinosis Syndrome. McCarthy, C; Carey, B; Trapnell, BC. Chest. 2019; 155:450-452.

57 - Lung Diseases Associated With Disruption of Pulmonary Surfactant Homeostasis. Nogee, LM; Trapnell, BC. Kendig's Disorders of the Respiratory Tract in Children. 2019.

Statin as a novel pharmacotherapy of pulmonary alveolar proteinosis. McCarthy, C; Lee, E; Bridges, JP; Sallese, A; Suzuki, T; Woods, JC; Bartholmai, BJ; Wang, T; Chalk, C; Carey, BC; et al. Nature Communications. 2018; 9.

Blood testing in the diagnosis of pulmonary alveolar proteinosis. McCarthy, C; Carey, B; Trapnell, BC. Lancet Respiratory Medicine. 2018; 6:e54-E54.

iPSC-Derived Macrophages Effectively Treat Pulmonary Alveolar Proteinosis in Csf2rb-Deficient Mice. Mucci, A; Lopez-Rodriguez, E; Hetzel, M; Liu, S; Suzuki, T; Happle, C; Ackermann, M; Kempf, H; Hillje, R; Kunkiel, J; et al. Stem Cell Reports. 2018; 11:696-710.